论文部分内容阅读
目的:探讨miRNA-145在肾癌中的临床意义及其分子机制。方法:通过实时定量PCR检测和比较16例肾癌患者的肿瘤组织及癌旁正常肾组织中miRNA-145的表达,并分析miRNA-145的表达水平与肾癌患者病理特征及临床分级的相关性。进一步采用实时定量PCR检测和比较肾癌细胞株786-O、769P及正常肾细胞株HK2中miRNA-145表达量,通过转染miRNA-145 mimics和阴性对照miRNA至769P、786-O肾癌细胞株后观察癌基因(bcl-2、e2f3、cdk6、ccnd1)mRNA的表达。结果:肾癌组织中miRNA-145的表达显著低于癌旁正常肾组织(P<0.05),且与肾癌的直径、病理核分级及临床分级呈显著负相关(P<0.05)。肾癌细胞株769P、786-O中miRNA-145的表达显著低于正常HK-2肾细胞(P<0.05),而转染miRNA-145 mimics的769P、786-O细胞中多个癌基因(bcl-2、e2f3、cdk6、ccnd1)的mRNA表达均较阴性对照组显著降低(P<0.05)。结论:MiRNA-145在肾癌中呈低表达,可能通过调控多个癌基因的表达在肾癌的发生发展过程中发挥重要的作用。
Objective: To investigate the clinical significance of miRNA-145 in renal cell carcinoma and its molecular mechanism. Methods: The real-time quantitative PCR was used to detect and compare the expression of miRNA-145 in tumor tissues and adjacent normal renal tissues of 16 patients with renal cell carcinoma. The correlation between the expression of miRNA-145 and pathological features and clinical grade of renal cell carcinoma was analyzed . Furthermore, real-time quantitative PCR was used to detect and compare the miRNA-145 expression in 786-O, 769P and HK2 cell lines. The miRNA-145mimics and negative control miRNAs were transfected into 769P and 786-O renal cancer cells The expression of oncogenes (bcl-2, e2f3, cdk6, ccnd1) mRNA was observed after the strain. Results: The expression of miRNA-145 in renal cell carcinoma was significantly lower than that in adjacent normal tissues (P <0.05), and was negatively correlated with the diameter, pathological nuclear grade and clinical grade (P <0.05). The expression of miRNA-145 in renal cancer cell lines 769P, 786-O was significantly lower than that in normal HK-2 renal cells (P <0.05), whereas the number of oncogenes in 769P and 786-O cells transfected with miRNA-145 mimics bcl-2, e2f3, cdk6, ccnd1) mRNA expression were significantly lower than the negative control group (P <0.05). Conclusion: The low expression of MiRNA-145 in renal cell carcinoma may play an important role in the development of renal cell carcinoma by regulating the expression of multiple oncogenes.